Scarica l'app Stockscreener
82.25
1.09%
-0.91
Dopo l'orario di chiusura:
82.05
-0.20
-0.24%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ILMN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$83.16
Aprire:
$83.19
Volume 24 ore:
1.73M
Relative Volume:
0.78
Capitalizzazione di mercato:
$13.02B
Reddito:
$4.34B
Utile/perdita netta:
$-965.00M
Rapporto P/E:
-13.55
EPS:
-6.07
Flusso di cassa netto:
$869.00M
1 W Prestazione:
-2.41%
1M Prestazione:
+5.22%
6M Prestazione:
-41.21%
1 anno Prestazione:
-22.98%
Intervallo 1D:
$81.75
$84.35
Intervallo di 1 settimana:
$78.79
$84.35
Portata 52W:
$68.70
$156.66
Illumina Inc Stock (ILMN) Company Profile
Nome
Illumina Inc
Settore
Industria
Telefono
(858) 202-4500
Indirizzo
5200 ILLUMINA WAY, SAN DIEGO, CA
Confronta ILMN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
82.25 | 13.34B | 4.34B | -965.00M | 869.00M | -6.07 |
|
TMO
Thermo Fisher Scientific Inc
|
398.36 | 152.41B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
192.15 | 136.31B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
522.21 | 41.46B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
113.94 | 32.18B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
147.37 | 24.40B | 15.50B | 1.33B | 2.16B | 7.34 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-04 | Reiterato | Citigroup | Neutral |
| 2025-02-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-02-10 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-02-07 | Downgrade | TD Cowen | Buy → Hold |
| 2024-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2024-11-12 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-10-17 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-08-28 | Aggiornamento | Argus | Hold → Buy |
| 2024-08-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-08-14 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-01-16 | Downgrade | HSBC Securities | Buy → Hold |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-11-10 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Iniziato | Bernstein | Underperform |
| 2023-07-05 | Ripresa | JP Morgan | Neutral |
| 2023-01-25 | Downgrade | Argus | Buy → Hold |
| 2023-01-05 | Iniziato | Scotiabank | Sector Perform |
| 2022-12-12 | Downgrade | Citigroup | Neutral → Sell |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-04 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-07-13 | Downgrade | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Aggiornamento | Stifel | Hold → Buy |
| 2022-01-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Iniziato | Barclays | Underweight |
| 2020-12-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-10-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Downgrade | Stifel | Buy → Hold |
| 2020-09-22 | Downgrade | UBS | Buy → Neutral |
| 2020-09-21 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Downgrade | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-04-24 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Illumina Inc Borsa (ILMN) Ultime notizie
Does Illumina (ILMN) Have Good Long-Term Growth Prospects? - Insider Monkey
Nucleic Acid Isolation and Purification Market Size, Trends & - openPR.com
Illumina DNA Test Tech Accused of Infringing Hospital Patent (1) - Bloomberg Law News
Microbiome Sequencing Market Outlook 2025-2029 | Affordable Sequencing Instruments Expand Market Access for Smaller Labs - Yahoo
Digital Genome Market Deep Research Report on AI-Driven DNA Analysis Trends | Illumina, Thermo Fisher Scientific - openPR.com
Forensic Genomics Market Research 2025Global Trends, Opportunity, and Forecasts 2020-2030 - GlobeNewswire Inc.
Cancer Profiling Market Is Booming So Rapidly 2025-2032 - openPR.com
Hereditary Testing MarketGlobal Industry Trends, Opportunity, and Forecast, 2020-2030: Key Players Like Illumina and Myriad Genetics Leading the Charge - Yahoo
Next-Gen RNA Sequencing Market | Personalized Medicine & Future - openPR.com
Gene Panel Market Projected to Witness Massive GrowthIllumina, Inc., Thermo Fisher Scientific - openPR.com
Illumina Connected Insights - Technology Networks
Illumina Inc (ILMN) Stock Price Down 3.31% on May 30 - GuruFocus
Genotyping Assay Market Deep Research Report Highlights Key AdvancementsIllumina, Thermo Fisher Scientific - openPR.com
Illumina’s PromoterAI unlocks rare disease clues in noncoding genome - statnews.com
Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain? - Yahoo Finance
Epigenetics Market Analysis 2025-2033: Advances in DNA - openPR.com
Illumina introduces PromoterAI for rare disease diagnosis By Investing.com - Investing.com South Africa
Illumina Inc.: Tackling Global Headwinds With Strategic Market Diversification! - Smartkarma
Illumina, Inc. (ILMN) Unveils AI Breakthrough for Rare Disease Diagnosis - Insider Monkey
Illumina introduces PromoterAI for rare disease diagnosis - Investing.com Australia
Operating a speedy, high-tech NGS lab in remote Australia - Illumina
Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis - PR Newswire
Bioinformatics Market Detailed in New Research ReportThermo Fisher Scientific, Illumina - openPR.com
DNA giant Illumina spawned an ecosystem of competitors and customers - Endpoints News
Illumina widens access to cancer tests with Medicare and new CDx - Yahoo Finance
Patent Fight Breaks Out over Genetic Sequencing - Orthopedics This Week
Illumina at Bernstein Conference: Strategic Insights and Challenges - Investing.com
Transcript : Illumina, Inc. Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-28-2025 02 - marketscreener.com
Stifel Affirms Buy Rating on Illumina (ILMN) Stock - MSN
Illumina Expands Clinical Oncology Portfolio Unlocking New Standard of Care and Access to Precision Therapies - marketscreener.com
Illumina Expands Clinical Oncology Portfolio Unlocking New Standard Of Care And Access To Precision Therapies - marketscreener.com
Gene Expression Software Market Growth Projected at CAGR of 7.8% - openPR.com
Lab-on-a-chip and Microarrays (Biochip) Market Generated - openPR.com
Illumina expands oncology portfolio with new FDA-approved test By Investing.com - Investing.com Canada
Illumina expands oncology portfolio with new FDA-approved test - Investing.com
Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies - PR Newswire
Stifel maintains Illumina stock buy rating, $135 target - Investing.com
Illumina's TSO Comprehensive Earns Japan's Approval: Stock to Gain? - Yahoo Finance
Illumina at ESHG 2025 - Illumina
Video: How researchers are moving multiomics forward with Illumina technology - Illumina
GC Genome plans $30M IPO to diversify genomic products, suppliers - BioWorld MedTech
Microfluidic Market Is Booming Worldwide | Agilent Technologies, Inc., Illumina, Inc., Perkinelmer, Inc. - openPR.com
DNA Forensic Solution Market Size, Share & Trend, Regional - openPR.com
Single Cell Genome Sequencing Market to Witness Massive Growth - openPR.com
Illumina’s SWOT analysis: genetic giant’s stock faces China headwinds By Investing.com - Investing.com Nigeria
Illumina’s SWOT analysis: genetic giant’s stock faces China headwinds - Investing.com
Cell-Free DNA Isolation and Extraction Market - GlobeNewswire Inc.
Cathie Wood Reiterates 'Profound' AI Application In Healthcare As Researchers Discover 'Cancer Survival Outcomes' By Facial Photograph Analysis: Here Are The Stocks That Could BenefitInvesco QQQ Trust, Series 1 (NASDAQ:QQQ), Illumina (NASDAQ:IL - Benzinga
Life Sciences Tools & Services Stocks Q1 Recap: Benchmarking Illumina (NASDAQ:ILMN) - Yahoo Finance
Tumor Profiling Market May Set New Growth Story | Illumina Inc., - openPR.com
Illumina Approves Key Proposals at Annual Meeting - TipRanks
Illumina Inc Azioni (ILMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):